BLUE - bluebird bio, Inc. Forward P/S Multiple

Corporate emblem and logo of bluebird bio, Inc. (BLUE)

bluebird bio, Inc. (BLUE) is expanding access to gene therapy through partnerships with insurance companies and clinics. This P/S trend chart reflects fundamental stability, where 0.50 becomes the new value for this metric. The company's developments aim to replace lifelong treatment for rare blood pathologies. However, a critical liquidity shortage and a single-product profile necessitate an urgent update to the sales strategy.

BLUE bluebird bio Inc.: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 06/07/2025

Analytical breakdowns for bluebird bio, Inc.

- current price and projected stock value:
Fundamental company valuation:bluebird bio, Inc BLUE
Product sample of bluebird bio, Inc.

This ratio determines the market value of the business relative to projected revenue, allowing investors to assess the premium paid for future cash flows. Analyzing the expected P/S of bluebird bio, Inc. (BLUE) reveals a compression of the multiple, which, given the company's development cycle independent of macroeconomic trends, transforms the asset into an undervalued defensive tool with resilient internal demand.

Competitors of bluebird bio, Inc. (BLUE)

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT: Future Price to Revenue|Forward P/S Multiple TWST (Twist Bioscience Inc)|Market Cap to Expected Sales Ratio 10x Genomics Corp (TXG)|intelliatx.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke STOK|biolifesolutions.com (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|Forward Price-to-Revenue Multiple Sionna Therapeutics, Inc. (SION)|Forward Price-to-Revenue Multiple PRME (Prime Medicine Bio)|Market Cap to Expected Sales Ratio Taysha|uniQure Pharma - Forward Price-to-Revenue Multiple|MeiraGTx Holdings plc - Price-to-Projected Revenue Ratio|regenxbio.com - Forward P/S Multiple|Solid Bio (SLDB) - Forward Price-to-Revenue Multiple|OCGN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Therapeutics)|Forward P/S Multiple RCKT|Price-to-Projected Revenue Ratio FDMT (4D Molecular Therapeutics Inc)|Forward P/S Multiple LXEO (Lexeo Therapeutics Inc.)|Forward Price to Sales KRRO|EDIT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Silence Therapeutics SLN|ProQR Therapeutics NV (PRQR) - Price-to-Projected Revenue Ratio|Codexis Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Sangamo BioSciences|Market Cap to Projected Revenue NAUT (Nautilus Biotechnology)|Price-to-Projected Revenue Ratio metagenomi.co (MGX)|DTIL: Future Price to Revenue|Price-to-Projected Revenue Ratio Generation Bio Co. GBIO|BOLD: Market Cap to Projected Revenue|XCUR: Forward Price-to-Revenue Multiple|Imunon (IMNN) - Forward Price-to-Revenue Multiple|PHIO (RXi Pharmaceuticals) - Forward Price-to-Revenue Multiple|MBIO (Mustang Bio Inc) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio TransCode Therapeutics, Inc.|Forward P/S Multiple bionanogenomics.com|Forward P/S Multiple APDN|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.